Compounds having the formula
1
are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
N-1- or N-3-substituted thieno[2,3-d]imidazol-2-one derivatives are selectively obtained after N-alkylation of thiaisatoic anhydrides followed by formation of the N-substituted aminocarbonyl azides and Curtius rearrangement, (C) 1999 Elsevier Science Ltd. All rights reserved.
ANTI-INFECTIVE AGENTS
申请人:ABBOTT LABORATORIES
公开号:EP1560827B1
公开(公告)日:2010-12-29
US7902203B2
申请人:——
公开号:US7902203B2
公开(公告)日:2011-03-08
[EN] IL4I1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'IL4I1 ET PROCÉDÉS D'UTILISATION
申请人:MERCK SHARP & DOHME
公开号:WO2021226003A1
公开(公告)日:2021-11-11
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.